Needham & Company
-
Regulus Announces Pricing of Public Offering of Common Stock
-
Regulus to Present at the 16th Annual Needham Healthcare Conference
-
Needham & Company Downgrades Regulus Therapeutics (RGLS) to Hold
-
Regulus Therapeutics (RGLS): Cutting PT to $10 - Needham & Company
-
Streetinsider.com's Hot Lunchtime Reads 6/7: (BIIB) (YHOO) (VRX) (RGLS) (TSLA)
-
Needham & Company Affirms Regulus Therapeutics (RGLS) at 'Buy'; Says Role of RG-101 in HCV Remains Unclear
-
Needham & Company Reiterates Bullish View on Regulus Therapeutics (RGLS) Following Latest Data
-
Notable Analyst Rating Changes 11/24: (SCTY) (LL) (KATE) Upgraded; (CBI) (VZ) (XOM) Downgraded
-
Pre-Open Stock Movers 11/24: (RNA) (CIMT) (PTP) Higher; (LGF) (TSL) (CBI) Lower (more...)
-
Regulus Therapeutics (RGLS) 5.29M Offering Prices at $17/Share
-
Regulus Therapeutics (RGLS) Reports $80M Common Stock Offering
-
Regulus Therapeutics (RGLS) Announces $80M Common Stock Offering
-
Regulus Therapeutics (RGLS) PT Lifted to $18 at Needham & Company on Surprisingly Strong RG-101 Data in HCV
-
Regulus Therapeutics (RGLS) Bullish Stance Reiterated at Needham & Company Post Q1
-
Regulus Therapeutics (RGLS) Target Raised to $14 at Needham & Company
-
Regulus Therapeutics (RGLS) Prices 4.5M Shares at $9.50
-
Regulus Therapeutics (NASDAQ: RGLS) Clinical Candidate in HCV Nominated; Reiterate Buy - Needham & Company
-
Needham & Company Starts Regulus Therapeutics (RGLS) at Buy
-
Regulus Therapeutics (RGLS) IPO Closes 5% Higher

